This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase III Study of NK105 in Patients With Breast Cancer

This study has been completed.
Information provided by (Responsible Party):
Nippon Kayaku Co.,Ltd. Identifier:
First received: July 17, 2012
Last updated: February 1, 2017
Last verified: February 2016
To verify the non-inferiority of NK105, a paclitaxel-incorporating micellar nanoparticle, to paclitaxel in terms of the progression-free survival in patients with metastatic or recurrent breast cancer.

Condition Intervention Phase
Breast Cancer Nos Metastatic Recurrent Drug: NK105 Drug: Paclitaxel Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-national Phase III Clinical Study Comparing NK105 Versus Paclitaxel in Patients With Metastatic or Recurrent Breast Cancer

Resource links provided by NLM:

Further study details as provided by Nippon Kayaku Co.,Ltd.:

Primary Outcome Measures:
  • Progression free survival [ Time Frame: 4.2 years ]

Enrollment: 436
Study Start Date: July 2012
Study Completion Date: January 2017
Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NK105 Drug: NK105
IV, Weekly
Active Comparator: Paclitaxel Drug: Paclitaxel
IV, Weekly

Detailed Description:
This study is a randomized, open-label, multi-national phase III study.

Ages Eligible for Study:   20 Years to 74 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent of the patient signed by herself.
  • Histologically confirmed metastatic or recurrent adenocarcinoma of the breast.
  • Aged 20 to 74 at the time of informed consent.

Exclusion Criteria:

  • Prior systemic chemotherapy with taxane anticancer drugs for metastatic or recurrent breast cancer.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01644890

Japan Sites
Tokyo, etc., Japan
Sponsors and Collaborators
Nippon Kayaku Co.,Ltd.
Study Director: Call +81-3-6731-5200 Mon - Fri 9 AM - 5 PM (Japan Time) Nippon Kayaku Co.,Ltd.
  More Information

Responsible Party: Nippon Kayaku Co.,Ltd. Identifier: NCT01644890     History of Changes
Other Study ID Numbers: A3105301
Study First Received: July 17, 2012
Last Updated: February 1, 2017

Keywords provided by Nippon Kayaku Co.,Ltd.:
NK105, Paclitaxel, Breast cancer, Micelle

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017